GLP1R and obesity disorder: With the current pathophysiological data, clinical evidence, and recent innovations about the relevant role of GLP-1 RA in preventing HFpEF and its effects on reverse remodeling and clinical outcomes, important mechanistic questions remain in patients with obesity, metabolic syndrome, or in obese type II diabetic patients.